Advanced Filters
noise
Found 811 clinical trials
S Shanna C Trenaman

Lemborexant for Insomnia in a Patient With Dementia: An N-of-1 Trial

Insomnia is a highly common, chronic disorder that is distressful for the patient but also for caregivers and can give rise to a heavy burden on the healthcare team. Sleeping aids like benzodiazepines and other sedatives (e.g., zolpidem, zopiclone) have been widely used to help treat insomnia. However, sleeping aids …

years of age All Phase 4
J JiSu Jeong

Confirmatory Clinical Trial for Verifying the Efficacy and Safety of 'ALZGUARD' as a Digital Dementia Diagnostic Aid-Tool for the Diagnosis of the Major Neurocognitive Disorders

The goal of this clinical trial is to evalute the efficacy of ALZGUARD, a smartphone-based digital therapeutic(DTx), in comparison to diagnosis by medical doctors, as weel as to assess the safety of the application.

55 - 85 years of age All Phase N/A

Web-based Cognitive Behavioral Treatment for Insomnia in Dementia Caregivers

Over the next 30 years, more than 10 million persons living with dementia in the United States will receive care at home from an unpaid and untrained family caregiver. At home care is preferred by caregivers and persons with dementia alike, but increases the caregiver's risk of insomnia and related …

18 years of age All Phase N/A
S Shanshan Wang

A Robot-assisted Tailored Activity Programme for People With Dementia and Their Caregivers

To assess the feasibility and preliminary efficacy of the tailored activity programme on improving the physical inactivity of the caregiving dyads.

18 years of age All Phase 1
M Maya Elias, PhD, RN

A Multi-Modal Combination Intervention to Promote Cognitive Function in Older Intensive Care Unit Survivors

Up to 25% of intensive care unit (ICU) survivors experience cognitive impairment comparable in severity to mild Alzheimer's disease and related dementias after hospital discharge. Older ICU survivors (ages 60 and older) are at highest risk for delirium and subsequent cognitive impairment, which contribute to higher risk for cognitive decline …

60 years of age All Phase N/A

Compare and Evaluate the Safety and PK Data of a Single Dose Administration of 'AD-115A' or 'AD-1151'

The study compare and evaluate the safety and pharmacokinetic characteristics of a single dose administration of 'AD-115A' or 'AD-1151' in healthy adults.

19 years of age All Phase 1

A Study to Evaluate the Safety and Pharmacokinetics of AD-116 and AD-1161 in Healthy Adult Male Subjects

A Study to Evaluate the Safety and Pharmacokinetics of AD-116 and AD-1161 Under Fed Conditions in Healthy Adult Male Subjects

19 years of age Male Phase 1

An Open-Label Study of ML-007C-MA in Adults With Alzheimer's Disease Psychosis

ML-007C-MA-222 is a 52-week, flexible-dose, open-label extension study designed to evaluate the long-term safety, tolerability, and effectiveness of ML007C-MA in participants with ADP who have completed the antecedent study (ie, Study ML-007C-MA-221).

55 - 91 years of age All Phase 2
C Camillo Marra, MD

Autonomic Involvement in Patient With Cognitive Decline

Prospective interventional study with a device for comparing autonomic parameters among patients with different forms of cognitive decline

50 - 85 years of age All Phase N/A
B Bjorn Meijers, MD, PhD

Treatment of AD With IgE Specific Immunoadsorption (IGEIAAD)

Removal of IgE through adsorption of IgE on a specially designed column after apheresis of blood has the potential to improve the severity of atopic dermatitis. In this study the investigators will treat patients with a severe form of Atopic dermatitis not responding or having to much side effects to …

18 - 70 years of age All Phase 2

Simplify language using AI